| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Arcadia Biosciences (NASDAQ:RKDA) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Arcadia Biosciences beat estimated earnings by 19.0%, reporting an EPS of $-2.1 versus an estimate of $-2.58.
Revenue was up $170 thousand from the same period last year.
Last quarter the company beat on EPS by $1.3 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Arcadia Biosciences's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -3.19 | -4.80 | -6.85 | -6.80 |
| EPS Actual | -1.89 | -2.64 | -10.86 | -6.31 |
| Revenue Estimate | 1.55M | 1.82M | 1.40M | 2.00M |
| Revenue Actual | 1.60M | 1.39M | 1.51M | 1.00M |
To track all earnings releases for Arcadia Biosciences visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RKDA
